Patent 9845355 was granted and assigned to Genentech on December, 2017 by the United States Patent and Trademark Office.
The present invention is directed to anti-CD79b antibodies with specific hypervariable region sequences in the heavy and light chain variable domains as enumerated in the SEQ ID NOs described herein.